In Leishmania infantum–endemic countries, controlling infection within dogs, the domestic reservoir, is critical to public health. There is a need for safe vaccines that prevent canine progression with disease and transmission to others. Protective vaccination against Leishmania requires mounting a strong, inflammatory, Type 1 response. Three commercially available canine vaccines on the global veterinary market use saponin or inflammatory antigen components (Letifend) as a strong pro-inflammatory adjuvant. There is very little information detailing safety of saponin as an adjuvant in field trials. Safety analyses for the use of vaccine as an immunotherapeutic in asymptomatically infected animals are completely lacking. Leishmania infantum, the causative agent of canine leishmaniasis, is enzootic within U.S. hunting hounds. We assessed the safety of LeishTec® after use in dogs from two different clinical states: 1) without clinical signs and tested negative on polymerase chain reaction and serology or 2) without clinical signs and positive for at least one Leishmania diagnostic test. Vaccine safety was assessed after all three vaccinations to quantify the number and severity of adverse events. Vaccinated animals had an adverse event rate of 3.09%, whereas placebo animals had 0.68%. Receiving vaccine was correlated with the occurrence of mild, site-specific, reactions. Occurrence of severe adverse events was not associated with having received vaccine. Infected, asymptomatic animals did not have a higher rate of adverse events. Use of vaccination is, therefore, likely to be safe in infected, asymptomatic animals.
Read the full article in The American of Tropical Medicine and Hygiene.
More from CNAS
CommentaryRetooling U.S. Security Sector Assistance
One of America’s most important foreign policy tools is not fit for purpose....
By Stephen Tankel & Tommy Ross
CommentaryConventional-Nuclear Integration in the Next National Defense Strategy
The next NDS must build on the limited progress that has been made to integrate conventional and nuclear strategy, planning, doctrine, and capabilities....
By John K. Warden
CommentarySharper: U.S. Strategy in the Middle East
CNAS experts are sharpening the conversation surrounding the future of U.S. strategy in the Middle East....
By Kaleigh Thomas, Chris Estep & Cole Stevens
CommentarySpace Force should break the mold in recruiting and retaining talent
We need a diverse talent pool that better reflects America in 2020....
By Eric Fanning